What is a stock summary page? Click here for an overview.
Business Description
JCR Pharmaceuticals Co Ltd
NAICS : 325412
SIC : 2834
ISIN : JP3701000006
Share Class Description:
TSE:4552: Ordinary SharesDescription
JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.48 | |||||
Equity-to-Asset | 0.5 | |||||
Debt-to-Equity | 0.62 | |||||
Debt-to-EBITDA | 24.01 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 1.85 | |||||
Beneish M-Score | -2.64 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.1 | |||||
3-Year EBITDA Growth Rate | -11 | |||||
3-Year EPS without NRI Growth Rate | -7 | |||||
3-Year FCF Growth Rate | 36.4 | |||||
3-Year Book Growth Rate | 9.9 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 43.44 | |||||
9-Day RSI | 46.35 | |||||
14-Day RSI | 46.35 | |||||
3-1 Month Momentum % | -13.67 | |||||
6-1 Month Momentum % | -21.08 | |||||
12-1 Month Momentum % | -41.12 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.48 | |||||
Quick Ratio | 0.86 | |||||
Cash Ratio | 0.4 | |||||
Days Inventory | 791.91 | |||||
Days Sales Outstanding | 153.02 | |||||
Days Payable | 38.61 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 3.89 | |||||
3-Year Dividend Growth Rate | -3.9 | |||||
Forward Dividend Yield % | 3.89 | |||||
5-Year Yield-on-Cost % | 11.4 | |||||
3-Year Average Share Buyback Ratio | -0.3 | |||||
Shareholder Yield % | -1.12 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 70.87 | |||||
Operating Margin % | -2.94 | |||||
Net Margin % | -0.65 | |||||
FCF Margin % | 20.6 | |||||
ROE % | -0.42 | |||||
ROA % | -0.22 | |||||
ROIC % | -0.32 | |||||
3-Year ROIIC % | -3.37 | |||||
ROC (Joel Greenblatt) % | -0.63 | |||||
ROCE % | -0.47 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 15.76 | |||||
Shiller PE Ratio | 13.23 | |||||
PS Ratio | 1.83 | |||||
PB Ratio | 1.2 | |||||
Price-to-Tangible-Book | 1.27 | |||||
Price-to-Free-Cash-Flow | 8.93 | |||||
Price-to-Operating-Cash-Flow | 6.92 | |||||
EV-to-EBIT | -251.23 | |||||
EV-to-Forward-EBIT | 18.7 | |||||
EV-to-EBITDA | 59.22 | |||||
EV-to-Forward-EBITDA | 15.14 | |||||
EV-to-Revenue | 2.28 | |||||
EV-to-Forward-Revenue | 3.95 | |||||
EV-to-FCF | 10.99 | |||||
Price-to-GF-Value | 0.33 | |||||
Price-to-Projected-FCF | 1.64 | |||||
Price-to-DCF (FCF Based) | 0.21 | |||||
Price-to-Median-PS-Value | 0.33 | |||||
Price-to-Net-Current-Asset-Value | 13.04 | |||||
Earnings Yield (Greenblatt) % | -0.39 | |||||
FCF Yield % | 11.53 | |||||
Forward Rate of Return (Yacktman) % | 7.51 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
JCR Pharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil 円) | 35,033 | ||
EPS (TTM) (円) | -1.87 | ||
Beta | 0.08 | ||
3-Year Sharpe Ratio | -1.19 | ||
3-Year Sortino Ratio | -1.29 | ||
Volatility % | 39.47 | ||
14-Day RSI | 46.35 | ||
14-Day ATR (円) | 19.895136 | ||
20-Day SMA (円) | 517.75 | ||
12-1 Month Momentum % | -41.12 | ||
52-Week Range (円) | 466 - 900 | ||
Shares Outstanding (Mil) | 121.82 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
JCR Pharmaceuticals Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
JCR Pharmaceuticals Co Ltd Stock Events
Event | Date | Price (円) | ||
---|---|---|---|---|
No Event Data |
JCR Pharmaceuticals Co Ltd Frequently Asked Questions
What is JCR Pharmaceuticals Co Ltd(TSE:4552)'s stock price today?
The current price of TSE:4552 is 円514.00. The 52 week high of TSE:4552 is 円900.00 and 52 week low is 円466.00.
When is next earnings date of JCR Pharmaceuticals Co Ltd(TSE:4552)?
The next earnings date of JCR Pharmaceuticals Co Ltd(TSE:4552) is .
Does JCR Pharmaceuticals Co Ltd(TSE:4552) pay dividends? If so, how much?
The Dividend Yield %  of JCR Pharmaceuticals Co Ltd(TSE:4552) is 3.89% (As of Today), Highest Dividend Payout Ratio of JCR Pharmaceuticals Co Ltd(TSE:4552) was 0.66. The lowest was 0.16. And the median was 0.38. The  Forward Dividend Yield % of JCR Pharmaceuticals Co Ltd(TSE:4552) is 3.89%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |